Evommune, Inc. 8-K

What Happened

• Evommune, Inc. (EVMN) filed a Form 8‑K on May 7, 2026, announcing it issued a press release with a business update and its financial results for the quarter ended March 31, 2026 (Item 2.02). The press release is furnished as Exhibit 99.1 to the 8‑K.
• On the same date the company updated its corporate presentation to reflect business updates and posted it in the “Investors & Media” section of its website (ir.evommune.com); that presentation is furnished as Exhibit 99.2 (Item 7.01). The filing is signed by President and CEO Luis Peña.

Key Details

• Filing date: May 7, 2026.
• Quarter covered: Quarter ended March 31, 2026 (Q1 2026).
• Press release: Furnished as Exhibit 99.1 to the Form 8‑K.
• Investor presentation: Updated May 2026 and furnished as Exhibit 99.2; available at ir.evommune.com (website content not incorporated by reference).

Why It Matters

• The 8‑K confirms Evommune has publicly released its Q1 2026 results and refreshed investor materials — primary sources for revenue, expense, cash runway, program updates, and other metrics that investors use to assess near‑term performance.
• Retail investors should review the Exhibit 99.1 press release and the updated presentation (Exhibit 99.2) for the actual financial figures, operational highlights, and any forward‑looking commentary; the Form 8‑K itself documents the release and where to find the full details.